Argen-X (0QW0) - Total Liabilities

Latest as of December 2024: €679.80 Million EUR ≈ $794.76 Million USD

Based on the latest financial reports, Argen-X (0QW0) has total liabilities worth €679.80 Million EUR (≈ $794.76 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Argen-X - Total Liabilities Trend (2010–2024)

This chart illustrates how Argen-X's total liabilities have evolved over time, based on quarterly financial data. See 0QW0 working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Argen-X Competitors by Total Liabilities

The table below lists competitors of Argen-X ranked by their total liabilities.

Company Country Total Liabilities
CP ALL Public Company Limited
BK:CPALL-R
Thailand ฿612.28 Billion
Insurance Australia Group Ltd
AU:IAG
Australia AU$19.83 Billion
Onto Innovation Inc
NYSE:ONTO
USA $264.18 Million
ALTEOGEN Inc
KQ:196170
Korea ₩216.61 Billion
Juniper Networks Inc
NYSE:JNPR
USA $5.26 Billion
Uni-President Enterprises Corp
TW:1216
Taiwan NT$525.35 Billion
Pershing Square Inc.
NYSE:PS
USA $106.00 Million
Jiangsu Etern Co Ltd
SHG:600105
China CN¥5.75 Billion

Liability Composition Analysis (2010–2024)

This chart breaks down Argen-X's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 0QW0 stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 7.29 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.13 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.11 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Argen-X's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Argen-X (2010–2024)

The table below shows the annual total liabilities of Argen-X from 2010 to 2024.

Year Total Liabilities Change
2024-12-31 €679.80 Million
≈ $794.76 Million
+52.78%
2023-12-31 €444.95 Million
≈ $520.19 Million
+38.80%
2022-12-31 €320.56 Million
≈ $374.77 Million
+1.43%
2021-12-31 €316.05 Million
≈ $369.50 Million
-47.79%
2020-12-31 €605.36 Million
≈ $707.72 Million
+40.84%
2019-12-31 €429.81 Million
≈ $502.49 Million
+837.86%
2018-12-31 €45.83 Million
≈ $53.58 Million
+47.05%
2017-12-31 €31.16 Million
≈ $36.43 Million
-30.11%
2016-12-31 €44.59 Million
≈ $52.13 Million
+369.65%
2015-12-31 €9.49 Million
≈ $11.10 Million
-7.36%
2014-12-31 €10.25 Million
≈ $11.98 Million
+124.36%
2013-12-31 €4.57 Million
≈ $5.34 Million
-27.24%
2012-12-31 €6.28 Million
≈ $7.34 Million
+55.30%
2011-12-31 €4.04 Million
≈ $4.73 Million
+99.25%
2010-12-31 €2.03 Million
≈ $2.37 Million
--

About Argen-X

LSE:0QW0 UK
Market Cap
$28.99 Billion
€24.80 Billion EUR
Market Cap Rank
#1796 Global
#6 in UK
Share Price
€764.20
Change (1 day)
-1.62%
52-Week Range
€459.05 - €803.70
All Time High
€803.70
About

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more